Stay current on changes and developments in corporate law with a wide variety of resources and tools.
July 22 — AbbVie Inc. investors cannot pursue claims that seek to hold Abbott Laboratories directors liable for damages that might result from a whistle-blower lawsuit, according to a July 21 Delaware Chancery Court ruling.
Vice Chancellor Sam Glasscock III refused to set aside a mutual release of liability entered into between Abbott Laboratories and its spin-off, on the grounds that the investors lacked standing to derivatively sue on behalf of AbbVie.
The release prevented the plaintiffs from derivatively suing Abbott directors for bad faith or lack of oversight in connection with the marketing of the drug Tricor, an asset transferred in the spin-off and the subject of the whistle-blower lawsuit.
Because the plaintiffs were not AbbVie shareholders at the time of the alleged wrong—the release's approval—they requested that the court find equitable standing under its ruling in Shaev v. Wyly. They claimed that an exception to Delaware's standing rule—8 Del. C. §327—was warranted to redress a wrong to AbbVie that would otherwise go unremedied if the release was approved.
However, Glasscock held that “an equitable override” of the rule was inapplicable because the plaintiffs failed to plead facts showing that AbbVie was harmed from the alleged wrongdoing.
“Even if the [whistle-blower] Action results in some kind of payout for which AbbVie is responsible because of the transfer of that liability from Abbott, there would remain a daunting leap between AbbVie's monetary liability for Abbott's off-label marketing of TriCor and Abbott directors being personally liable for bad faith or oversight in connection with that marketing,” he wrote.
To contact the reporter on this story: Michael Greene in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Ryan Tuck at email@example.com
The opinion is available at http://www.bloomberglaw.com/public/document/IN_RE_ABBVIE_INC_STOCKHOLDER_DERIVATIVE_LITIGATION_No_9983VCG_201.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)